Olumacostat glasaretil: Ph III CLAREOS-1 and CLAREOS-2 started

Dermira began the identical, double-blind, vehicle-controlled, international Phase III CLAREOS-1 and CLAREOS-2 trials to evaluate twice-daily 5% topical olumacostat glasaretil for 12 weeks in about 1,...